Duke Energy Corp (NYSE:DUK) (In Eye of Expert, Trend Analysis after Current Fluctuation? Get Her Free Report) reported a number of partner firms it will employ to build three previously released solar projects in North Carolina by the end of 2015. The firm will construct as well as own a number of of the largest solar facilities on the East Coast, totaling 128 megawatts of capacity. Duke Energy Corp (NYSE:DUK) saw as a loser stock in last session, fell -0.69% to finished at $73.87 with the overall traded volume of 3.06 million shares.
Tiffany & Co. (NYSE:TIF) (Read Report! How TIF Noticeable Reacts on News Jerk?) aims to use the net proceeds from the notes proposing to redeem all $100,000,000 principal amount outstanding of its 9.05% Series A Senior Notes due December 23, 2015; all $125,000,000 principal amount outstanding of its 10.0% Series A-2009 Senior Notes due February 13, 2017. The firm aims to use any remaining net proceeds from the sale of the notes for general corporate purposes. Tiffany & Co. (NYSE:TIF) settled at the price of $97.02 with negative change of -2.54% as its highest price in last session was noted at $98.90. On analysts consideration, the mean recommendation of this week is 2.3, [(Strong Buy 1.0 – 5.0 (Sell)] as compare to last week mean recommendation of 2.3, which indicates zero volatility in recommendations.
Thoratec Corporation (NASDAQ:THOR) (Find Your Indebt Report on THOR, to be Informed Well) expects third quarter revenue $102 million to $107 million as compared to $109.54M Capital IQ Consensus. D. Keith Grossman has been appointed President and Chief Executive Officer, effective immediately. Thoratec Corporation (NASDAQ:THOR) has its total traded volume during previous session was 4.42 million shares with share price change of 6.12% to settled at $27.74.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (Watch Expert Views In Detail on PGNX Here) presents long term follow-up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma; ‘results propose that treatment with Azedra has significant patient benefit both in symptom control as well as cancer control. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) after opening at $5.17 hit its day high price of $5.26 moreover fell -3.74% to closed at $4.89. The consensus average revenue estimates are $2.93m for latest quarter, at the same time as 3 experts predict $30.26m revenues for the next three months of 2014.
For latest Market Updates Subscribes Here
